Startup | February 16, 2022
GOQii raises US $ 50 million Series C funding
Funding to grow the insurance and digital therapeutics vertical in India
Funding to grow the insurance and digital therapeutics vertical in India
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
She holds a Masters degree in Genetics along with a Ph.D. in Biochemistry
The recommendation has been sent to the DCGI for approval
Last year, the company's early-stage breast cancer detection test became the first such test to receive the Breakthrough Device Designation
These results will be presented on 17 February at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
Launches a host of innovative products & solutions across the entire flexible packaging value chain in October - December 2021
It will open new frontier for south-to-south collaboration and innovation transfer
Rimegepant is the first oral calcitonin gene-related peptide receptor antagonist to demonstrate positive results in a pivotal trial in the Asia Pacific
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
Subscribe To Our Newsletter & Stay Updated
